Lexicon Pharmaceuticals, Inc. (LXRX) Given Average Recommendation of “Hold” by Brokerages

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has received a consensus recommendation of “Hold” from the ten brokerages that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $25.25.

Several research analysts have weighed in on LXRX shares. Zacks Investment Research cut shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 27th. Needham & Company LLC reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Monday, July 30th. Stifel Nicolaus reissued a “buy” rating and issued a $23.00 price target (down from $24.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday, July 31st. BidaskClub cut shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 31st. Finally, ValuEngine cut shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 17th.

Institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. raised its holdings in Lexicon Pharmaceuticals by 4.6% in the 2nd quarter. BlackRock Inc. now owns 4,422,293 shares of the biopharmaceutical company’s stock valued at $53,066,000 after acquiring an additional 195,461 shares during the period. Tocqueville Asset Management L.P. bought a new position in Lexicon Pharmaceuticals in the 2nd quarter valued at about $164,000. Schwab Charles Investment Management Inc. raised its holdings in Lexicon Pharmaceuticals by 6.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 241,061 shares of the biopharmaceutical company’s stock valued at $2,893,000 after acquiring an additional 14,426 shares during the period. LPL Financial LLC grew its position in shares of Lexicon Pharmaceuticals by 34.1% during the 1st quarter. LPL Financial LLC now owns 29,172 shares of the biopharmaceutical company’s stock worth $250,000 after purchasing an additional 7,426 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Lexicon Pharmaceuticals during the 2nd quarter worth approximately $205,000.

Shares of LXRX stock traded down $0.12 on Friday, reaching $8.97. The stock had a trading volume of 263,323 shares, compared to its average volume of 552,690. The company has a debt-to-equity ratio of 8.85, a quick ratio of 2.83 and a current ratio of 2.90. The stock has a market cap of $902.48 million, a price-to-earnings ratio of -7.06 and a beta of 0.73. Lexicon Pharmaceuticals has a 12 month low of $7.42 and a 12 month high of $13.97.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.07. The company had revenue of $6.90 million for the quarter, compared to analysts’ expectations of $12.56 million. Lexicon Pharmaceuticals had a negative net margin of 168.23% and a negative return on equity of 1,247.65%. Lexicon Pharmaceuticals’s quarterly revenue was down 74.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.29) EPS. Sell-side analysts predict that Lexicon Pharmaceuticals will post -1.29 EPS for the current fiscal year.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Further Reading: Retained Earnings

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply